Option chain shows key data for Can Fite Biofarma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Can Fite Biofarma.

Can Fite Biofarma (AMEX:CANF) Stock, Option Chain

Can Fite Biofarma

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RARE

RNXT

RZLT

SVMH

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotech

Equities

Penny Stocks

Health Care

General

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of 

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?

Price Target

Small Cap

Analyst Ratings

ARVN

GOGL

MATX

MEDP

NRDS

SWAV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Canfor Corp

CANFOR PULP PRODUCTS INC by Canfor Pulp Products, Inc.

Canfor Pulp Products Inc

Raymond James analyst Steve Hansen upgrades Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) from Market Perform to Outperform and raises the price target from $58 to $60.

Upgrades

Raymond James Upgrades Nutrien to Outperform, Raises Price Target to $60

Warrior Met Coal's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) short percent of float has risen 14.86% since its last report. The company recently reported that it has 5.26 million shares sold short, which is 13.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Warrior Met Coal Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Warrior Met Coal has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Warrior Met Coal's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Warrior Met Coal's peer group average for short interest as a percentage of float is 3.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(HCC) - Analyzing Warrior Met Coal's Short Interest

PENN Entertainment's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NYSE">PENN</a>) short percent of float has fallen 7.46% since its last report. The company recently reported that it has 18.40 million shares sold short, which is 13.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PENN Entertainment Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247019_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PENN Entertainment has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PENN Entertainment's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PENN Entertainment's peer group average for short interest as a percentage of float is 4.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About PENN Entertainment?

Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares jumped <a href="https://www.benzinga.com/quote/CRDO">almost 40% in early trading on Tuesday</a>.
The visibility into the company's growth inflection in the back half of the year improved significantly, according to BofA Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02943eaaa00018d9399/vivek-arya">Analyst Vivek Arya</a> upgraded the rating for Credo Technology from Underperform to Buy while raising the price target from $27 to $80.
The Credo Technology Thesis: The company delivered a "solid beat and material raise" quarter, Arya said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Credo Technology's outlook suggests "the start of a multi-year adoption cycle for its Active Electrical Cable (AEC) product that enables power-efficient AI clusters," he added.
The company's earnings call addressed the concerns around the market for AEC, "with 3x 10% customers," including Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) as well as "growing momentum in other adjacent areas (optical DSP, line card PHY, retimer)," the analyst stated.
Credo Technology is likely to generate robust results in the back half of fiscal 2025, "driven by strong AI growth at Amazon Web Services, a key customer (and investor)," he further wrote.
CRDO Price Action: Shares of Credo Technology had risen by 49.24% to $71.34 at the time of publication on Tuesday.
Read More: • <a href="https://www.benzinga.com/24/12/42284734/why-credo-technology-group-shares-are-trading-higher-by-40-here-are-20-stocks-moving-premarket">Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket</a>
Photo: Courtesy Credo

Analyst Color

Long Ideas

Tech

AMZN

CRDO

MSFT

TSLA

Credo Technology Analyst Double Upgrades AI Play, Raises Forecast By Almost 200%

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 12.63% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 6.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247013_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

INSM

How Is The Market Feeling About Insmed?

Needham analyst Mike Matson reiterates Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and maintains $112 price target.

Reiteration

Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target

<a href="https://www.foxbusiness.com/video/5640669329001" title="https://www.foxbusiness.com/video/5640669329001">https://www.foxbusiness.com/video/5640669329001</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Daly Says Neutral Rate Is Closer To 3%; We Can Take Our Time Getting To Neutral; We Will Continue To Have Restrictive Policy Until Inflation Gets To 2%; Don't See Any Reason For A Rate Hike; Trajectory Of Change Is Down

Amazon Aurora DSQL provides a distributed SQL database with 99.999% multi-Region availability, virtually unlimited scalability, strong consistency, and zero infrastructure management

AWS Announces New Database Capabilities Including Amazon Aurora DSQL

Fed's Daly Says Employers Are Filling Positions For Core Work, But Not Taking A Lot Of Risk

Fed's Daly Says Even If We Do Another Rate Cut, Policy Will Remain Restrictive; Trade Issues Don't Usually Derail Growth, Economy Adjusts; We Are Prepared To Assess Things, But Need To See Policies Before Fed Reacts

Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares are trading higher Tuesday following the company's announcement that it acquired real estate for seven of its core metal recycling facilities, a move expected to enhance its financial and strategic position. Here&#8217;s <a href="https://www.benzinga.com/quote/GWAV">what you need to know.</a>
What To Know: The acquisition was completed through a purchase from the company&#8217;s CEO Danny Meeks. The strategic initiative is expected to eliminate $1.7 million in annual rent expenses, substantially improve Greenwave&#8217;s cash flow and reduce operating costs, providing the company with more financial flexibility.
The acquired facilities are spread across critical locations in Virginia including Norfolk, Virginia Beach and Portsmouth. The sites are strategically important due to their proximity to major infrastructure, including the largest U.S. Naval Base in Norfolk and the Port of Virginia in Portsmouth.
Additionally, the facilities benefit from grandfathered operational licenses that create high barriers to entry in the tightly regulated metal recycling industry, further strengthening Greenwave's competitive advantage.
Greenwave operates 13 metal recycling facilities across Virginia, North Carolina and Ohio, supplying steel mills and industrial companies with ferrous and non-ferrous metals. The company&#8217;s operations play a vital role in the recycling supply chain, contributing raw materials for critical infrastructure and national security projects, including U.S. warships. 
GWAV Price Action: Greenwave Technology Solutions shares were up 47% at 53 cents at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-1024x545.png" alt="" class="wp-image-674878" style="width:434px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42296197/ondo-finance-ethereums-blackrock-backed-tokenization-crypto-surges-38-why-is-ondo-going-up">Ondo Finance, Ethereum&#8217;s BlackRock-Backed Tokenization Crypto, Surges 38%: Why Is ONDO Going Up?</a></li>
</ul>
Image via Shutterstock.

GWAV

What's Going On With Greenwave Technology Solutions Stock Today?

Fed's Daly In Fox Business Network Interview Says Us Economy Is In A Really Good Place; December Rate Cut Is Absolutely Not Off The Table; Timing Of Rate Cut Is Up For Debate, But Need To Keep Moving Policy Rate Down; We Need An Open Mind;  Labor Market Is Completely In Balance, Not A Source Of Inflation; We Knew Inflation Woul Be A Bumpy Ride, It Is Moving Down Gradually, But More Work To Do

WIIM

Lion Electric shares are trading higher. The company recently announced amendments to senior credit instruments and workforce reductions.

Leerink Partners analyst Jeffrey La Rosa maintains Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform and raises the price target from $79 to $91.

JANX

Leerink Partners Maintains Outperform on Janux Therapeutics, Raises Price Target to $91

FromSoftware's award-winning Elden Ring is a franchise fans won't need to say goodbye to just yet, but don't expect a <a href="https://www.benzinga.com/general/gaming">direct sequel.</a>
In a recent <a href="https://game.watch.impress.co.jp/docs/interview/1644616.html">interview</a> with Japanese outlet Game Watch, Hidetaka Miyazaki, the studio&#8217;s acclaimed creator, confirmed that Elden Ring 2 is not part of the company&#8217;s plans.
See Also:<a href="https://www.benzinga.com/general/gaming/24/12/42270630/gta-6-fans-analyze-playlists-and-combat-ai-chaos-one-year-after-first-trailer"> GTA 6 Fans Analyze Playlists And Combat AI Chaos, One Year After First Trailer</a>
Speaking after Elden Ring DLC Shadow of the Erdtree earned top honors at this year's PlayStation Awards, Miyazaki clarified the studio's direction. 
&#8220;At this point, we are not considering developments such as &#8220;Elden Ring 2&#8221;, he said. &#8220;However, this does not mean that we are denying the development of the IP &#8216;Elden Ring&#8217;.&#8221; 
He added: &#8220;As for &#8216;what will we do then?&#8217;, FromSoftware is running multiple projects as usual. Among them, there are various variations of projects, so I hope you will look forward to them.&#8221;
<h3 class="wp-block-heading">Speculation: What's Next For FromSoftware?</h3>
Beyond Elden Ring, FromSoftware appears to be juggling a slate of unannounced projects. Earlier this year, now-deleted job listings sparked speculation of a potential new Armored Core installment, with mentions of robot characters fueling the theory. Given the studio's legacy in mecha-themed titles, such a pivot would align with its history of alternating between genres.
Moreover, the studio's parent company Kadokawa has acknowledged <a href="https://www.benzinga.com/general/gaming/24/11/42098643/kadokawa-ceo-confirms-sonys-buyout-interest-no-decision-has-been-made">acquisition interest</a> from Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42141838/elden-ring-creator-hidetaka-miyazaki-teases-various-new-projects-in-development">Elden Ring Creator Hidetaka Miyazaki Teases &#8216;Various New Projects&#8217; In Development</a></li>
</ul>
Image credits: Shutterstock.

Gaming

SONY

'We Are Not Considering Elden Ring 2,' Says FromSoftware's Miyazaki

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $2 price target.

APTO

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target

At the recent <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event, industry leaders tackled how stablecoins are reshaping finance, spurring adoption among institutional investors, and addressing operational hurdles in digital markets. The panel, moderated by BlackRock's Kyle Braden, featured Jennifer O'Rourke of DTCC Digital Assets, Chuck Mounts of S&amp;P Global Ratings, and David Alderman of Franklin Templeton, who provided valuable perspectives.
<h4 class="wp-block-heading">Stablecoins: A Bridge To Institutional Participation</h4>
Mounts described stablecoins as a critical link between traditional finance and the digital asset ecosystem. 
"Stablecoins are&#8230; positioned to be the accelerant to the mass adoption for tradfi firms and crypto financial capabilities in the marketplace," he explained. Mounts shared how S&amp;P Global's stablecoin stability assessment tool is helping institutions evaluate the risk of stablecoins losing their peg to fiat currencies, adding a layer of confidence for new entrants to the market.
Mounts emphasized the need for stablecoins to underpin the tokenization of real-world assets, citing the potential for increased liquidity and operational efficiency. "Policy formation is the single most important non-technology catalyst," he added, predicting that stablecoin legislation could be the first crypto-related law passed by the new Congress.
<h4 class="wp-block-heading">Overcoming Liquidity And Settlement Challenges</h4>
O'Rourke highlighted the practical challenges tied to stablecoin adoption, particularly regarding liquidity pools and settlement speed. She explained that tokenized assets offer fast and programmable transactions, but the supporting payment systems often lag. 
"If you're going to buy a tokenized asset&#8230; you need to be able to pay for it as quickly as you want to receive it," O'Rourke stated. Addressing this disparity, she argued, is essential for widespread adoption.
O'Rourke also touched on the fragmented nature of liquidity in digital markets, where isolated pools make seamless transactions difficult. She stressed the importance of standardizing processes to connect these pools, paving the way for a more cohesive digital marketplace.
<h4 class="wp-block-heading">Regulatory Clarity On The Horizon</h4>
Alderman of Franklin Templeton pointed to recent shifts in U.S. regulation as promising for stablecoins and digital assets. "I think a lot of crypto companies that were thinking about leaving the U.S. will stay, just because now it's a more pro-crypto stance," he said. 
Alderman added that regulatory clarity would encourage companies to invest in new technologies and infrastructure, further supporting the adoption of stablecoins.
Mounts agreed, describing the potential for stablecoin legislation to reduce uncertainty and enable financial institutions to participate more actively in the market. He also noted that stablecoins could play a role in dollarizing foreign economies, citing their use in markets like Argentina as an example.
<h4 class="wp-block-heading">Building A Path Forward</h4>
As the discussion wrapped up, panelists agreed that while stablecoins present challenges, their potential to transform finance is undeniable. The ongoing work to address operational hurdles and regulatory ambiguity will lay the groundwork for broader adoption, making stablecoins a cornerstone of future financial systems.
From their use in tokenizing real-world assets to their potential impact on global markets, stablecoins are proving to be a driving force in bringing digital assets into the institutional fold.
Photo by Igor Faun on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

'Policy Formation Will Be Critical': Experts Weigh In On Stablecoin Adoption

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) announced Tuesday that it has received final acceptance from the TSX Venture Exchange for its previously announced acquisition of a Canadian licensed producer of cannabis, AgMedica Bioscience Inc.
The acquisition, arranged through an agreement with Callisto Capital Corp. on October 28, 2024, was made in exchange for a <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">$6.3 million unsecured convertible debenture</a>. As a result of receiving the acceptance, Decibel has completed the conversion of the convertible debenture, pursuant to which it has issued 114.55 million common shares to Callisto.
The conversion of the convertible debenture was conditional upon receipt of final TSXV acceptance for the acquisition of AgMedica pursuant to Exchange Policy 5.3. This policy would have required approval from disinterested shareholders if Callisto became a major controller of the company. However, because the company has finished its recent private funding, Callisto will not control the company after the bond is converted. Therefore, approval from disinterested shareholders is not needed for the conversion.
Read Also: <a href="https://www.benzinga.com/24/12/42272602/cannabis-retail-giant-high-tide-launches-cabana-club-membership-program-in-us-eu-and-uk-with-new-product-categories">Cannabis Giant High Tide Taps Into $113 Billion Global E-Commerce Market With New Product Categories</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
On Nov. 25, the Calgary, Alberta-based cannabis company confirmed completion of the second and final closing of non-brokered private placement of its common shares at $0.06 per share. At the second closing of the offering, it issued 19.65 million shares for gross proceeds of <a href="https://www.benzinga.com/news/financing/24/11/42164794/decibel-cannabis-raises-1-18m-secures-capital-for-agmedica-bioscience-integration">roughly $1.18 million.</a>
Previously, Decibel projected that AgMedica could <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">contribute $30 million of net revenue</a> and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro-forma basis.
The transaction is expected to materially expand Decibel&#8217;s international footprint with EU GMP certification that enables export of flower and a variety of extract products, with proven sales to seven different countries including Australia, Denmark, Germany, Israel, Norway, Spain and the United Kingdom.
Price Action
Decibel shares closed Monday's market session 6.62% higher at $0.0499 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">Canadian Cannabis Co. Decibel Reports 12% YoY Drop In Q3 Revenue But Increases Gross Margin To 53%</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/12/42280135/health-canada-cuts-14-6m-from-cannabis-program-amid-federal-austerity">Health Canada Cuts $14.6M From Cannabis Program Amid Federal Austerity</a></li>
</ul>
Photo: Courtesy of pashabo&nbsp;via Shutterstock

Cannabis

DBCCF

TSXV:DB

Decibel Receives Final TSX Venture Exchange Acceptance For AgMedica Acquisition And Debenture Conversion

Goldman Sachs analyst Gustavo Miele initiates coverage on Afya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) with a Sell rating and announces Price Target of $16.

Initiation

AFYA

Goldman Sachs Initiates Coverage On Afya with Sell Rating, Announces Price Target of $16

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Buy and maintains $35 price target.

ATYR

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

Can-Fite BioPharma files to sell 1.77B  shares of common stock for holders

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has received Israeli Ministry of Health approval to proceed with a Phase IIa c...

Can-Fite Advances Pancreatic Cancer Drug Trial

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has secured a promising financial future through a licensing deal with Vetbiol...

Can-Fite BioPharma's Lucrative Veterinary Licensing Deal

Can-Fite gains after agreement for animal arthritis drug

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma Ltd., a biotech firm targeting oncological and inflammatory diseases, announce...

Can-Fite's Namodenoson Gains FDA Orphan Status

Can-Fite stock rallies 17% on FDA orphan drug designation

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has announced promising results from a clinical study on dogs with osteoarthri...

Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix

Can-Fite BioPharma (CANF) announced an update related to the intellectual property, IP, status of its lead drug candidate Namodenoson, currently be...

Can-Fite BioPharma announces an update related to IP status of Namodenoson

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Can-Fite BioPharma (CANF – Research Report). The associated price ...

Promising Developments and Expanding Indications for Can-Fite BioPharma's Namodenoson: Analyst Recommends Buy

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has achieved a significant milestone by dosing the first patient in its Phase ...

Can-Fite BioPharma Advances in Pancreatic Cancer Trial

Press Releases

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Earnings

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Significant Positive Results from Osteoarthritis Clinical  Study in Dogs Treated with Piclidenoson

Legal

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Comments

Can Fite Biofarma

Can Fite Biofarma (CANF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga